Publications by authors named "F M A C Martens"
Palladium(ii)-catalyzed dehydrogenative coupling of aliphatic olefins would enable an efficient route to (conjugated) dienes, but remains scarcely investigated. Here, 2-hydroxypyridine (2-OH-pyridine) was found to be an effective ligand for Pd(ii) in the activation of vinylic C(sp)-H bonds. While reoxidation of Pd(0) is challenging in many catalytic oxidations, one can avoid in this reaction that the reoxidation becomes rate-limiting, even under ambient O pressure, by working in coordinating solvents.
View Article and Find Full Text PDFArticle Synopsis
- The Revi system, developed by BlueWind Medical, is an innovative implantable device designed to treat urgency urinary incontinence, marking the first FDA-cleared neuromodulation device that can be used without prior conservative treatments.
- In a study involving 151 women, 79% of those assessed at the 24-month mark showed significant improvement in their condition, with consistent efficacy over time and high rates of participant satisfaction.
- The results highlight the Revi system's durability, effectiveness, and safety, with no serious adverse events reported throughout the study period.
Article Synopsis
- - Several risk models exist for predicting atherosclerotic cardiovascular disease in asymptomatic individuals, but they often have limited effectiveness, while the coronary artery calcium score (CACS) shows promise, especially in ruling out severe cases.
- - A CACS of 0 can lower perceived cardiovascular risk, but this status requires reassessment every 5 to 10 years; conversely, higher CACS values can identify individuals at greater risk who may benefit from preventive medications.
- - Upcoming updates to Dutch guidelines aim to better integrate CACS into cardiovascular risk assessments, while also advocating for coronary CT angiography (CCTA) to gather more detailed information, particularly for symptomatic or high-risk patients.
Purpose: To determine whether patients with a ruptured brain arteriovenous malformation (rBAVM) would benefit from an early embolization.
Methods: rBAVM treated first by embolization between March 2002 and May 2022 were included. Embolization was defined early (Group 1) when performed within 10 days postbleeding.
Aims: Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment effects may vary between individuals. This study aimed to determine the relative and absolute effects of icosapent ethyl on MACE according to baseline cardiovascular disease (CVD) risk in patients with atherosclerotic cardiovascular disease (ASCVD).
Methods And Results: Participants from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) with ASCVD were included (n = 5785).